An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

Inclusion Criteria:

- Ability to comply with the study protocol, in the investigator's judgment

- Participation in Study GA39688 or GA39855, including completion of endoscopy and other
assessments at Week 24, without discontinuation of study drug

- Completion of eDiary daily assessments for at least 4 out of 7 days in the week prior
to the Week 24 visit of Study GA39688 or GA39855

- For women of childbearing potential: agreement to remain abstinent or use acceptable
contraceptive methods during the treatment period and for 60 days after the last dose
of study drug

Exclusion Criteria:

- Anaphylaxis/hypersensitivity related to study drug in Study GA39688 or GA39855

- Serious adverse events related to study drug in Study GA39688 or GA39855 that the
investigator or Sponsor determines may jeopardize the patient's safety if he or she
continues in the study

- Uncontrolled epistaxis within Study GA39688 or GA39855

- Pregnant or breastfeeding, or intending to become pregnant during the study or within
60 days after the last dose of omalizumab

- Any serious medical condition or abnormality in clinical laboratory tests that, in the
investigator's judgment, precludes the patient's safe participation in and completion
of the study